Singapore, Dec. 22 -- China-based Jacobio Pharma has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73.AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China.

Under the terms of the agreement, Jacobio will receive an upfront payment of $100 million, and is eligible for additional development and commercial milestone payments of up to $1.915 billion, as well as tiered royalties on net salesachieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China.

JAB-23E73 is...